Edition:
United States

Alexion Pharmaceuticals Inc (ALXN.O)

ALXN.O on Nasdaq

126.00USD
8 Dec 2016
Change (% chg)

$0.38 (+0.30%)
Prev Close
$125.62
Open
$125.45
Day's High
$126.69
Day's Low
$123.13
Volume
1,914,177
Avg. Vol
1,917,449
52-wk High
$193.45
52-wk Low
$110.56

ALXN.O

Chart for ALXN.O

About

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company's marketed products... (more)

Overall

Beta: 1.41
Market Cap(Mil.): $28,170.03
Shares Outstanding(Mil.): 224.25
Dividend: --
Yield (%): --

Financials

  ALXN.O Industry Sector
P/E (TTM): 77.20 30.04 30.65
EPS (TTM): 1.63 -- --
ROI: 2.96 15.86 15.23
ROE: 4.39 16.96 16.56

BRIEF-Alexion Pharmaceuticals announces new data

* Alexion Pharmaceuticals Inc - new data from an analysis of patients enrolled in global atypical hemolytic uremic syndrome (aHUS) registry

Nov 17 2016

BRIEF-Paulson & Co cuts share stake in Alexion Pharmaceuticals, Johnson & Johnson

* Paulson & Co cuts share stake in Alexion Pharmaceuticals Inc by 15.0 percent to 227,700 shares

Nov 14 2016

BRIEF-Alexion says new long-term data show reduction in liver fibrosis and cirrhosis in cohort of patients with lysosomal acid lipase deficiency treated with Kanuma

* Alexion says new long-term data show reduction in liver fibrosis and cirrhosis in cohort of patients with lysosomal acid lipase deficiency treated with Kanuma

Nov 11 2016

BRIEF-Alexion Pharmaceuticals files for non-timely 10-Q

* Files for non-timely 10-Q Source text for Eikon: [ID:http://bit.ly/2fTifZm] Further company coverage:

Nov 09 2016

UPDATE 1-Alexion says investigating Soliris sales practices

Nov 10 Alexion Pharmaceuticals Inc said on Wednesday it was investigating allegations made by a former employee regarding sales practices involving its flagship and costly blood disorder drug Soliris.

Nov 09 2016

Alexion says investigating Soliris sales practices

Alexion Pharmaceuticals Inc said on Wednesday it was conducting an investigation into allegations made by a former employee regarding sales practices of blood disorder drug Soliris.

Nov 09 2016

Alexion says investigating Soliris sales practices

Nov 10 Alexion Pharmaceuticals Inc said on Wednesday it was conducting an investigation into allegations made by a former employee regarding sales practices of blood disorder drug Soliris.

Nov 09 2016

BRIEF-Alexion Pharmaceuticals posts Q3 non-gaap EPS of $1.23

* Q3 earnings per share view $1.17 -- Thomson Reuters I/B/E/S

Oct 27 2016

BRIEF-Alexion initiates simultaneous registration trials of ALXN1210 for patients with PNH and AHUS

* Alexion initiates simultaneous registration trials of ALXN1210 for patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (ahus)

Oct 27 2016

BRIEF-Alexion gets orphan drug designation for ALXN1007

* European Commission grants orphan drug designation to ALXN1007 for the treatment of patients with graft-versus-host disease (GVHD)

Aug 29 2016

Competitors

Earnings vs. Estimates